Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors

BACKGROUND: With the rapid development of immune checkpoint inhibitors and neoantigen (NeoV)-based personalized tumor vaccines, tumor immunotherapy has shown promising therapeutic results. However, the limited efficacy of available tumor vaccines impedes the development of personalized tumor immunot...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yang, Liu, Ye, Wang, Di, Bai, Hua, Wang, Zhijie, He, Xiran, Zhang, Pei, Tian, Jie, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883272/
https://www.ncbi.nlm.nih.gov/pubmed/35217574
http://dx.doi.org/10.1136/jitc-2021-003564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883272/
https://www.ncbi.nlm.nih.gov/pubmed/35217574
http://dx.doi.org/10.1136/jitc-2021-003564

Ejemplares similares